Arcus Biosciences (NYSE:RCUS) Reaches New 52-Week Low – Should You Sell?

Arcus Biosciences, Inc. (NYSE:RCUS)’s share price hit a new 52-week low on Tuesday . The stock traded as low as $9.01 and last traded at $9.42, with a volume of 1579786 shares traded. The stock had previously closed at $9.58.

Analysts Set New Price Targets

Several research analysts have recently weighed in on RCUS shares. HC Wainwright upgraded shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $18.00 to $24.00 in a research note on Wednesday, February 26th. Morgan Stanley dropped their price target on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Finally, Bank of America dropped their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $30.25.

Arcus Biosciences Stock Down 1.7 %

The stock has a market capitalization of $990.29 million, a P/E ratio of -2.99 and a beta of 1.36. The company’s 50-day moving average price is $12.67 and its 200 day moving average price is $15.10. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.14. The company had revenue of $36.00 million for the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. As a group, equities analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, CEO Terry J. Rosen bought 19,800 shares of Arcus Biosciences stock in a transaction dated Thursday, February 27th. The shares were purchased at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the acquisition, the chief executive officer now directly owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This represents a 0.78 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the sale, the chief financial officer now owns 60,138 shares in the company, valued at approximately $902,070. This trade represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 12.30% of the stock is currently owned by insiders.

Institutional Trading of Arcus Biosciences

Large investors have recently made changes to their positions in the business. R Squared Ltd bought a new stake in shares of Arcus Biosciences in the 4th quarter worth about $26,000. Point72 Hong Kong Ltd bought a new stake in shares of Arcus Biosciences in the 3rd quarter worth about $47,000. Lazard Asset Management LLC increased its holdings in shares of Arcus Biosciences by 3,321.3% in the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock worth $93,000 after buying an additional 6,078 shares during the last quarter. US Bancorp DE increased its holdings in shares of Arcus Biosciences by 2,432.0% in the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock worth $103,000 after buying an additional 6,615 shares during the last quarter. Finally, Quest Partners LLC increased its holdings in shares of Arcus Biosciences by 40,904.3% in the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock worth $144,000 after buying an additional 9,408 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.